RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVAÂ for the Treatment of Cholangiocarcinoma

Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVAÂ ABC294640 for cholangiocarcinoma as well as a sevenyear marketing exclusivity period for the indication if approved for marketingA Phase IIa clinical s...